L. Ye, K. T. Yong, L. Liu, I. Roy, R. Hu, J. Zhu, H. Cai, W. C. Law, J. Liu, K. Wang, J. Liu, Y. Liu, Y. Hu, X. Zhang, M. T. Swihart, P.N. Prasad, “A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots,” Nat Nanotechnol, Vol. 7, No. 7, 2012, pp. 453-458.

has been cited by the following article:

• TITLE: Engineering Antibody Fragment with the Quantum Dot in Cancer Cell Imaging and Diagnosis

  AUTHORS: Lizhi Liu, Weiming Xu

  KEYWORDS: Quantum Dot; Antibody Fragment; Prostate Cancer; GRP78; scFv; UPR; Immunohistochemistry

  JOURNAL NAME: Engineering, Vol.4 No.10B, October 21, 2013

  ABSTRACT: The conjugates of monoclonal antibodies and nanoparticles, including quantum-dot(QD), offer significant advantages over conventional fluorescent probes to image and study biological processes. The extend stability, intense fluorescence and low toxicity of QDs are well suited for biological applications. In the present study, we used QD-conjugated anti-glucose-regulated protein 78(GRP78) antibody to examine the gene expression in prostate cancer cells under the unfolded protein response (UPR). QDs have got unique, simple and fast properties over current diagnostic techniques such as peroxidase-based immunohistochemical staining procedures, therefore the nanocarrier-conjugated antibody fragment has potential to become a new therapeutic tool for cancer diagnosis and treatment.